Lori J. Wirth, MD, Massachusetts General Hospital

Articles

Future Directions in Biomarker-Based Oncology

May 12th 2021

Experts in oncology discuss future directions in biomarker-driven therapy.

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

May 12th 2021

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Tumor Agnostic RET Inhibition: The ARROW Trial

May 5th 2021

Dr Jyoti Patel presents data from the ARROW clinical trial.

Tumor Agnostic RET Inhibition: The LIBRETTO-001 Trial

May 5th 2021

Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.

RET as a Therapeutic Target for Solid Tumors

April 28th 2021

Expert oncologists discuss RET-driven therapy for select solid tumors.

TRK Fusion Inhibitors in Clinical Practice

April 28th 2021

Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.

TRK Fusion Inhibitors in Tumor-Agnostic Clinical Trials

April 21st 2021

Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.

Treatment Options for NRTK Fusion–Positive Solid Tumors

April 21st 2021

Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.

NRTK Fusions in Oncology 

April 14th 2021

Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.

Solid Tumors: Unmet Needs Related to Biomarker-Driven Therapy

April 14th 2021

Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.

Companion Diagnostics in Oncology for Solid Tumors

April 7th 2021

Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors. 

Pan-Tumor Biomarker Testing in Oncology

April 7th 2021

A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.

Key Considerations for Biomarker Testing

March 31st 2021

Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.

Importance of Biomarker Testing for Solid Tumors

March 31st 2021

Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.

Treating BRAF V600 and NTRK Gene Fusion Positivity

February 11th 2021

The Future of RAI-Refractory DTC Management

February 11th 2021

Rationale for Sequencing in Second Line

February 4th 2021

LIBRETTO-001 Phase 1/2 Trial Overview

February 4th 2021

Advice for Managing RAI-Refractory DTC

January 28th 2021

Molecular Testing in Treatment Selection

January 28th 2021